Compare Moderna, Inc. (MRNA) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs TKO Group Holdings Inc — how do they compare? Moderna, Inc. trades at $63.33 (market cap $25.42B), while TKO Group Holdings Inc trades at $199.68 (market cap $14.27B). The key difference: Moderna, Inc. is the larger of the two by market cap, and TKO Group Holdings Inc pays a 1.59% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | TKO | |
|---|---|---|
Market Cap | $25.42B | $14.27B |
Sector | Health | Technology |
52-Week High | $81.80 | $224.96 |
52-Week Low | $22.36 | $176.49 |
Enterprise Value | $21.57B | $18.63B |
Dividend Yield | — | 1.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.65, up 5.09% on the day, with a bullish technical signal from moving averages and recent FDA approval of its mRNA flu vaccine mFLUSIVA for adults 50+. Despite negative net income margins and declining revenue since 2022, the company beat Q2 2026 EPS estimates and maintains a diversified pipeline in flu, oncology, and rare diseases. Cash flow improved in 2025 with positive net cash flow of $668 million.
The outlook hinges on pipeline execution beyond COVID-19, with growth opportunities in new vaccine approvals but significant risks from persistent losses and competitive pressures. Analyst consensus is cautious with a hold-heavy rating and $54.33 price target below the current price, indicating skepticism about near-term profitability.
TKO trades at $195.14, up 0.21% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $228.17. Recent Q2 2026 earnings of $1.34 per share missed estimates but revenue grew 18% year-over-year, prompting raised full-year guidance. The company maintains strong cash flow from operations of $1.8 billion in 2026 and a dividend payout, though high P/E of 68.47 signals premium valuation.
The stock offers upside potential from media rights and live event growth, but risks include earnings volatility and institutional selling. Analyst sentiment is overwhelmingly positive with 89% buy ratings, yet investors should weigh elevated valuation against execution risks in a competitive sports entertainment landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
